Emerging research shows mast cells play a role in the etiology of chronic rhinosinusitis with nasal polyps and may be a new ...
The approval is based on a multi-center, randomized, double-blind, placebo-controlled phase III clinical study to confirm the efficacy and safety of Stapokibart injection in treatment of patients with ...
AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...
RAPT (RAPT) stock rallied as much as 180% Monday after the company announced a licensing deal with China's Jemincare and a $150M private placement of its stock. Read more here.
HC Wainwright upgraded Aclaris Therapeutics (ACRS) to Buy with a $20 price target. Aclaris gains after licensing agreement ...
RAPT obtains worldwide rights excluding China - - Jemincare receives $35 million upfront payment, up to $672.5 million in milestone payments and high single-digit to low-double digit royalties on ...
Interleukins are cytokines produced and secreted mainly by CD3+ and CD4+ T lymphocytes. Interleukins promote development and differentiation of natural killer cells, T and B lymphocytes and ...
It starts with a stuffy nose, but soon your head feels like it’s caught in a vice. Nasal congestion and headaches often go ...
U.S. officials are moving to phase out the leading decongestant found in hundreds of over-the-counter medicines, concluding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback